Syndax Pharmaceuticals Inc at Barclays Global Healthcare Conference Transcript
(technical difficulty)
the Barclays Healthcare Conference in Miami. Do e-mail us or messages on Bloomberg, if you have any questions. My name is Peter Lawson. I'm one of the SMID cap biotech analyst at Barclays. I'm really delighted to have up on stage with this pretty broad representation of management from Syndax. So we've got Michael Metzger, CEO and Director; Anjali Ganguli, Chief Business Officer; and Keith Goldan, CFO.
Questions & Answers
So I guess first question is just around Menin inhibitor and the Phase II kind of how enrollment's going? And I'd love to know about this kind of the pace of enrollment -- so augment 101 kind of between the 2 different classes of the MPN1 versus rearranged or [KPM2]?
Maybe if you don't mind. First of all, thank you for having us. It's
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |